The new imaging agent [18 F]FPyPARP indicates promise for improved non-invasive imaging of abdominal lesions. Furthermore, we compared the state-of-the-art [18 F]PARPi and [18 F]FTT …

Apr 14, 2023 · Biomarkers to predict response are needed. [18F]FluorThanatrace ( [18F]FTT) is a PARPi-analog PET radiotracer that noninvasively measures PARP-1 expression. Herein, we …

[18F]FluorThanatrace ( [18F]FTT) is a radiolabeled poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that enables noninvasive quantification of PARP with potential to …

Purpose: Imaging of PARP expression has emerged as valuable strategy for prediction of tumor malignancy. While [18 F]PARPi and [18 F]FTT are already in clinical translation, both suffer …

Fluorine 18 (18F) fluorthanatrace (18F-FTT) is a PET radiotracer for imaging poly (adenosine diphosphate–ribose) polymerase-1 (PARP-1), an important target for a class of drugs known …

Mar 25, 2025 · Here, we evaluate a radiolabeled PARPi, [18 F]FluorThanatrace ( [18 F]FTT), as a functional biomarker of PARPi response in breast cancer.

Sep 6, 2021 · The new imaging agent [18 F]FPyPARP indicates promise for improved non-invasive imaging of abdominal lesions. Furthermore, we compared the state-of-the-art [18 …

Jun 2, 2022 · 18F-FluorThanatrace (18F-FTT) positron emission tomography (PET/CT) in prostate cancer measures in vivo PARP-1 expression and is associated with adverse …

Aug 1, 2022 · Introduction: We performed the first-in-human clinical trial to evaluate the expression of PARP-1, the target of PARP-inhibiting (PARPi) medications, in prostate cancer …

Fluorine 18 (18 F) fluorthanatrace (18 F-FTT) is a PET radiotracer for imaging poly (adenosine diphosphate–ribose) polymerase-1 (PARP-1), an important target for a class of drugs known …